Stockscreener 앱 받기
0.3349
0.77%
-0.0026
전일 마감가:
$0.3375
열려 있는:
$0.34
하루 거래량:
565.46K
Relative Volume:
0.29
시가총액:
$22.28M
수익:
-
순이익/손실:
$-17.78M
주가수익비율:
-0.6098
EPS:
-0.5492
순현금흐름:
$-10.52M
1주 성능:
-0.92%
1개월 성능:
+39.08%
6개월 성능:
-53.29%
1년 성능:
-82.47%
1일 변동 폭
$0.3267
$0.3481
1주일 범위
$0.3207
$0.4298
52주 변동 폭
$0.2201
$2.00
Fibrobiologics Inc Stock (FBLG) Company Profile
명칭
Fibrobiologics Inc
전화
281-671-5150
주소
455 E. MEDICAL CENTER BLVD, HOUSTON
FBLG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.3349 | 22.45M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-30 | 개시 | H.C. Wainwright | Buy |
| 2024-09-24 | 개시 | Maxim Group | Buy |
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
Risk Recap: Is FibroBiologics Inc stock a smart retirement pickJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Aug EndMonth: Why retail investors favor FibroBiologics Inc stockJuly 2025 Snapshot & Safe Swing Trade Setups - Bộ Nội Vụ
Levels Update: Why retail investors favor FibroBiologics Inc stock2025 AllTime Highs & Long-Term Safe Investment Ideas - Bộ Nội Vụ
How FibroBiologics Inc. stock benefits from strong dollarWeekly Trade Summary & Long-Term Growth Stock Strategies - Улправда
Why analysts remain bullish on FibroBiologics Inc. stockTrade Risk Summary & Consistent Profit Trading Strategies - Улправда
Will FibroBiologics Inc. stock remain a Wall Street favoriteWeekly Loss Report & Reliable Price Action Trade Plans - Улправда
Why FibroBiologics Inc. stock is a must watch in 2025July 2025 Breakouts & Verified Swing Trading Watchlists - Улправда
FibroBiologics faces Nasdaq delisting, plans reverse split - MSN
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 - Yahoo Finance
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 - Investing.com Nigeria
Why FibroBiologics Inc. (SG0) stock attracts wealthy investorsStock Market Trends & Minimize Portfolio Damage with Warnings - ulpravda.ru
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
How a little-known biotech uses fibroblast cells against chronic disease - Stock Titan
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at D. Boral Capital - Defense World
How interest rate cuts could boost FibroBiologics Inc. stock2026 world cup usa national team round of 16 defensive leaders possession football expert forecast insights - Улправда
FibroBiologics (FBLG) Rating Maintained as "Buy" by D. Boral Cap - GuruFocus
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference - The Manila Times
FibroBiologics reports positive results for disc degeneration therapy By Investing.com - Investing.com Nigeria
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte Spheroid Therapy for Degenerative Disc Disease - marketscreener.com
FibroBiologics reports positive results for disc degeneration therapy - Investing.com
FibroBiologics Announces Positive Preclinical Results for a - GlobeNewswire
Fibrobiologics files IND for CYPS-317 to treat psoriasis - BioWorld MedTech
San Bernardino Sun - FinancialContent
FibroBiologics Advances Psoriasis Therapy Pipeline Through FDA IND Filing For CYPS317 - Voice Of HealthCare
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at HC Wainwright - Defense World
FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split - TipRanks
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal By Investing.com - Investing.com South Africa
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal - Investing.com
FibroBiologics Received Notice of Delisting - TradingView — Track All Markets
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing - Investing.com Canada
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing By Investing.com - Investing.com South Africa
FBLG: HC Wainwright & Co. Reiterates Buy Rating with Price Targe - GuruFocus
Fibrobiologics stock rises after FDA filing for psoriasis treatment - Investing.com India
Fibrobiologics stock rises after FDA filing for psoriasis treatment By Investing.com - Investing.com South Africa
FibroBiologics files IND application for psoriasis treatment By Investing.com - Investing.com Nigeria
FibroBiologics files IND application for psoriasis treatment - Investing.com India
FibroBiologics Announces IND Filing for CYPS317 Therapy for Moderate to Severe Psoriasis - Quiver Quantitative
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis - Chartmill
[DEF 14A] FibroBiologics, Inc. Definitive Proxy Statement - Stock Titan
Why FibroBiologics Inc. stock remains resilientPortfolio Value Report & Entry Point Strategy Guides - Улправда
Activity Recap: Why FibroBiologics Inc. (SG0) stock attracts wealthy investorsJuly 2025 Analyst Calls & Long-Term Capital Growth Ideas - Улправда
Fibrobiologics Inc (FBLG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fibrobiologics Inc 주식 (FBLG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Khoja Hamid | Chief Scientific Officer |
May 27 '25 |
Buy |
0.84 |
20,000 |
16,800 |
31,250 |
4.73%
0.92%
자본화:
|
볼륨(24시간):